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Abstract
Background
Patients with chronic kidney disease (CKD) are at an increased risk of developing end-stage
renal disease (ESRD). We assessed for the first time whether urinary free light chains (FLC)
are independently associated with risk of ESRD in patients with CKD, and whether they
offer incremental value in risk stratification.
Materials and methods
We measured urinary FLCs in 556 patients with CKD from a prospective cohort study. The
association between urinary kappa/creatinine (KCR) and lambda/creatinine (LCR) ratios
and development of ESRD was assessed by competing-risks regression (to account for the
competing risk of death). The change in C-statistic and integrated discrimination improve-
ment were used to assess the incremental value of adding KCR or LCR to the Kidney Failure
Risk Equation (KFRE).
Results
136 participants developed ESRD during a median follow-up time of 51 months. Significant
associations between KCR and LCR and risk of ESRD became non-significant after adjust-
ment for estimated glomerular filtration rate (eGFR) and albumin/creatinine ratio (ACR),
although having a KCR or LCR >75th centile remained independently associated with risk of
ESRD. Neither KCR nor LCR as continuous or categorical variables provided incremental
value when added to the KFRE for estimating risk of ESRD at two years.
PLOS ONE | https://doi.org/10.1371/journal.pone.0197043 May 9, 2018 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Fenton A, Jesky MD, Webster R, Stringer
SJ, Yadav P, Chapple I, et al. (2018) Association
between urinary free light chains and progression
to end stage renal disease in chronic kidney
disease. PLoS ONE 13(5): e0197043. https://doi.
org/10.1371/journal.pone.0197043
Editor: Petter Bjornstad, University of Colorado
Denver School of Medicine, UNITED STATES
Received: October 25, 2017
Accepted: April 25, 2018
Published: May 9, 2018
Copyright: © 2018 Fenton et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Due to ethical
restrictions by the National Research Ethics Service
(NRES) Committee West Midlands-South
Birmingham, data cannot be shared publicly and is
subject to adherence to existing ethics approval.
Interested, qualified researchers can request the
data by contacting Penelope Gregory, REC
Manager, at NRESCommittee.westmidlands-
southbirmingham@nhs.net.
Funding: The Jabbs Foundation provided funding
towards the RIISC study. The Jabbs Foundation
Conclusions
Urinary FLCs have an association with progression to ESRD in patients with CKD which
appears to be explained to a degree by their correlation with eGFR and ACR. Levels above
the 75th centile do have an independent association with ESRD, but do not improve upon a
current model for risk stratification.
Introduction
Patients with chronic kidney disease (CKD) are at an increased risk of adverse health outcomes
including progression to end-stage renal disease (ESRD) and early mortality [1–6]. Risk pre-
diction models can be used to estimate an individual’s risk of ESRD, incorporating prognostic
factors such as age, gender, glomerular filtration rate (GFR), and level of albuminuria [7–9].
There is significant interest in identifying further prognostic factors, including urinary pro-
teins in addition to albumin, with a view to enhancing prognostic models and identifying
potential targets for novel interventions.
During the synthesis of intact immunoglobulins, light chains are produced in excess of
heavy chains, resulting in the release into the circulation of approximately 500 mg per day of
unbound free light chains (FLC) [10]. As monomeric FLCs (usually kappa) weigh ~25 kDa,
and dimeric FLCs (usually lambda) weigh ~50 kDa, they are filtered at the glomerulus and
then reabsorbed and metabolised in the proximal tubule [11]. Although small amounts of FLC
may be present from mucosal secretion from the urinary tract, the presence of significant FLC
in the urine implies either concentrations in the proximal tubule greater than can be reab-
sorbed, as may occur with excess monoclonal FLC production in plasma cell dyscrasias, or
renal disease with glomerular hyperfiltration and/or tubular dysfunction [12].
Previous work has demonstrated that urinary FLC concentration increases as estimated
GFR (eGFR) decreases, and urinary FLC may be more sensitive than albuminuria as a marker
of early CKD [13]. In patients with type 2 diabetes mellitus (DM), raised urinary concentra-
tions of FLC are detectable prior to the development of increased albuminuria [14, 15]. Uri-
nary FLC levels have also been shown to correlate with disease activity in IgA nephropathy
and lupus nephritis [16, 17].
Our objectives were to assess, for the first time, whether urinary FLC are independently
associated with risk of ESRD in patients with CKD, and whether measuring urinary FLC
improves upon an established model for risk stratification.
Materials and methods
We used data and samples from the Renal Impairment in Secondary Care (RIISC) Study (Clin-
icalTrials.gov: NCT01722383). The RIISC study is a prospective cohort study of patients with
CKD and the detailed methodology has been published previously [18].
In brief, patients in nephrology clinics at two renal centres were invited to participate if they
had high-risk CKD, defined as an eGFR < 30 mL/min/1.73m2, or an eGFR 30–59 mL/min/
1.73m2 with a decline of 5 mL/min/1.73m2 over a year or 10 mL/min/1.73m2 over 5 years
or an ACR 70 mg/mmol on three occasions. Patients were excluded if they had received
immunosuppression for immune-mediated renal disease or if they had started renal replace-
ment therapy (RRT, i.e. dialysis or kidney transplant). For this analysis, we also excluded
patients with a monoclonal gammopathy i.e. monoclonal gammopathy of undetermined
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significance (MGUS), including patients with an abnormal serum FLC isotype and a serum
kappa/lambda (κ/λ) FLC ratio outside of the renal reference range (0.37–3.1) [13, 19], or a
known diagnosis of myeloma, AL amyloidosis, or other monoclonal gammopathy of renal sig-
nificance. Participants were recruited between October 2010 and December 2015 and followed
up until they started RRT or died. The primary outcome of interest was progression to ESRD,
which was defined as the initiation of RRT and was captured using both centres’ local data-
bases of patients who have started dialysis or received a kidney transplant. Outcomes were
captured up to 31 January 2017 and patients who had not reached a study end-point were cen-
sored on this date. Ethical approval was granted by the South Birmingham Research Ethics
Committee (reference: 10/H1207/6). All patients provided written consent, and the study was
conducted in accordance with the Declaration of Helsinki.
Laboratory analyses
Serum and urine were processed immediately after collection according to pre-defined stan-
dard operating procedures and stored at -80˚C until analysis.
Urinary FLCs were measured by turbidimetry on a Roche Modular P analyser using the
Freelite™ immunoassay (The Binding Site Group Ltd, Birmingham, UK). To correct for varia-
tions in urine concentration, urinary FLCs were divided by urine creatinine concentration to
give urinary FLC/creatinine (FLC/Cr) ratios in mg/mmol, i.e. a kappa/creatinine ratio (KCR)
and a lambda/creatinine ratio (LCR). Serum creatinine measurements were performed on a
Roche Modular analyser using a rate-blanked and compensated Jaffe reaction, and eGFR was
calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equa-
tion [20]. Serum kappa (κ) and lambda (λ) FLC concentrations were measured by nephelome-
try on a Dade-Behring BN™ II System (Siemens AG, Erlangen, Germany) using the Freelite™
assay. Urine ACR was measured using a Roche Hitachi 702 analyser. Other biochemistry test-
ing was performed by the local clinical laboratories in accordance with the current standard of
care.
Blood pressure
Blood pressure (BP) was measured using the BpTRU automated device (BpTRU Medical
Devices, Coquitlam, BC, Canada) which obtains six BP readings after a five-minute rest period.
The systolic (SBP) and diastolic BP (DBP) are derived from the mean of the second to sixth
readings, and this method has been reported to be comparable to the mean daytime BP from
24-hour ambulatory BP monitoring [21]. Mean arterial pressure (MAP) was calculated as
((2 × DBP) + SBP) 3.
Statistical analyses
Statistical analyses were performed using SPSS Statistics 24 (Armonk, NY: IBM Corp, 2016)
and Stata 15 (College Station, TX: StataCorp, 2017). Baseline characteristics are presented as
a frequency and percentage for categorical variables, and a median and interquartile range
(IQR) for continuous variables.
Urinary FLC/Cr ratios were log-transformed prior to parametric testing. Their associations
with other continuous baseline variables were examined by scatter plots and Pearson’s correla-
tion coefficients. Correlation coefficients of 0.2, 0.5, and 0.8 were considered weak, moderate,
and strong, respectively [22]. To assess their association with categorical variables, between-
group differences were tested for using the Mann-Whitney U (two groups) and Kruskal-Wallis
(three or more groups) tests. Multiple linear regression was used to further assess the influence
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of serum FLC on urinary FLC/Cr ratios after adjustment for other significant determinants of
urinary FLC/Cr ratios (eGFR, ACR, DM, and renal diagnosis).
The associations between urinary FLC/Cr and progression to ESRD were assessed in uni-
variable and multivariable regression models. As 75 (13.5%) participants died without ESRD,
we used competing-risks regression based on the proportional subhazards model of Fine and
Gray [23], which allowed us to handle mortality as a competing event (simply censoring at
death in standard Cox regression models would have made the incorrect assumption that the
censored deceased participants remained at risk of developing ESRD). In the multivariable
models, we adjusted for confounding factors known to be associated with CKD progression:
eGFR (model 1); ACR (model 2); eGFR and ACR (model 3); age, gender, ethnicity, renal diag-
nosis, MAP, eGFR, and ACR (model 4). Subhazard ratios (SHR) are presented with 95% confi-
dence intervals (CI), which for continuous variables represented the risk of ESRD associated
with an increase of one standard deviation (SD). Urinary FLC/Cr ratios were analysed as both
full-range continuous variables and as categorical variables (comparing above versus below the
75th centiles). Competing-risks models were also built to include restricted cubic splines of uri-
nary FLC/Cr ratios to assess for non-linear associations between urinary FLC/Cr ratios and
risk of ESRD. Kaplan-Meier curves were plotted to show the cumulative incidence of ESRD by
quartiles of urinary FLC/Cr.
To examine whether urinary FLC/Cr provide any incremental value in risk stratification,
we chose the four-variable ‘Kidney Failure Risk Equation’ (KFRE) [9] as the baseline model for
comparison, which estimates an individuals’ risk of ESRD at two and five years. Binary logistic
regression models were fitted for the outcome of ESRD at two years. The baseline model con-
tained only the KFRE-calculated two-year risk of ESRD, calculated as:
1   0:9832e
ð  0:2201  ðage=10  7:036Þ þ 0:2467  ðmale   0:5642Þ  0:5567  ðeGFR=5  7:222Þ þ 0:4510  ðlogACR   5:137ÞÞ
(the four-variable, non-North America, two-year risk equation from eAppendix 2 of [24];
ACR was converted to mg/g before being entered into the model by dividing by 0.113).
KCR and LCR (separately) were added as continuous and categorical predictors to the base-
line KFRE model and the models compared. Overall model performance was estimated by
R2 (Nagelkerke, a version of the Cox & Snell R2 adjusted to cover the full range from 0 to 1
[25]), discrimination was assessed by the C-statistic, and calibration by the Hosmer-Lemeshow
goodness-of-fit test. The incremental value of adding KCR or LCR to the baseline model was
assessed by the change in C-statistic and by the reclassification measure Integrated Discrimina-
tion Index (IDI). The IDI is a measure of the extent to which adding a new marker to a model
correctly revises upward the predicted risk of individuals who experience an event and correctly
revises downward the predicted risk of individuals who do not experience an event [26, 27].
Results
Urinary FLCs were measured in 636 participants of the RIISC study. We excluded 41 patients
with a monoclonal gammopathy (21 with a serum κ/λ FLC ratio outside the renal reference
range, 15 with MGUS, and 5 with multiple myeloma), and also excluded 39 patients with uri-
nary FLC or creatinine results above or below the limits of detection so that accurate FLC/Cr
ratios could be calculated. Therefore, 556 participants were included for analysis with a median
follow-up time of 51 (IQR 46–60) months.
Baseline characteristics
The baseline characteristics of the study population are shown in Table 1. The cohort had a
median age of 64 (IQR 51–76) years, were 63% male, and 68% were of White ethnicity. The
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most common aetiologies of CKD were ischaemic/hypertensive nephropathy (28.9%), glomer-
ulonephritis (14.3%), and diabetic kidney disease (12.9%). Median eGFR was 25 (IQR 19–34)
mL/min/1.73m2 and median ACR was 28.1 (IQR 5.8–103.2) mg/mmol. Median urinary KCR
was 14.6 (IQR 7.1–27.7) mg/mmol and median LCR was 2.1 (IQR 1.0–5.1) mg/mmol.
Urinary FLC/Cr associations
The associations between urinary KCR and LCR with other baseline variables are shown in
Table 2. For comparison, the associations with ACR are also given. Urinary FLC/Cr ratios had
moderate positive correlations with serum FLC (sFLC), weak-to-moderate positive correla-
tions with ACR, and weak negative correlations with eGFR. The urinary FLC/Cr ratios, unlike
ACR, increased significantly with worsening CKD stage.
Table 1. Baseline characteristics of the study population (N = 556).
Characteristic Median (IQR) or N (%) Completeness of data (%)
Age (years) 64 (51–76) 100
Male gender 351 (63.1) 100
Ethnicity 100
White 380 (68.3)
South Asian 117 (21.0)
Black 56 (10.1)
Other 3 (0.5)
Co-morbidities 100
Diabetes mellitus 196 (35.3)
Ischaemic heart disease 120 (21.6)
Cerebrovascular disease 53 (9.5)
Peripheral vascular disease 53 (9.5)
COPD 57 (10.3)
Malignancy 71 (12.8)
Renal diagnosis 90
Ischaemic/hypertensive 145 (28.9)
Glomerulonephritis 72 (14.3)
Diabetic kidney disease 65 (12.9)
Polycystic kidney disease 29 (5.8)
Interstitial nephropathy 29 (5.8)
Reflux nephropathy 12 (2.4)
Other/uncertain 150 (29.9)
Estimated GFR (mL/min/1.73m2) 25 (19–34) 98
Urinary ACR (mg/mmol) 28.1 (5.7–103.2) 92
Systolic blood pressure (mmHg) 128 (116–144) 99
Diastolic blood pressure (mmHg) 76 (68–85) 99
Serum κ FLC (mg/L) 44.9 (29.5–67.0) 99
Serum λ FLC (mg/L) 32.5 (23.4–47.0) 99
Urinary KCR (mg/mmol) 14.6 (7.1–27.7) 100
Urinary LCR (mg/mmol) 2.1 (1.0–5.1) 100
Continuous variables are expressed as a median and interquartile range, and categorical variables are expressed as a frequency and percentage.
Abbreviations: ACR = albumin/creatinine ratio; COPD = chronic obstructive pulmonary disease; FLC = free light chains; GFR = glomerular filtration rate;
IQR = interquartile range; KCR = kappa/creatinine ratio; LCR = lambda/creatinine ratio.
https://doi.org/10.1371/journal.pone.0197043.t001
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Table 2. Associations between urinary free light chain/creatinine ratios and albumin/creatinine ratio with other baseline variables.
Variable Urinary kappa/creatinine ratio Urinary lambda/creatinine ratio Urinary albumin/creatinine ratio
Median (IQR) or r P Median (IQR) or r P Median (IQR) or r P
Age 0.109 0.010 0.012 0.77 -0.321 <0.0001
Gender 0.028 0.007 0.038
Male 16.2 (7.4–29.3) 2.3 (1.1–5.2) 32.5 (7.3–111.3)
Female 12.3 (6.3–26.5) 1.9 (0.7–4.3) 20.0 (4.4–83.2)
Ethnicity 0.007 0.001 <0.0001
White 13.1 (7.1–24.5) 1.9 (1.0–4.3) 16.9 (4.2–76.4)
South Asian 20.0 (8.4–37.2) 3.4 (1.5–7.9) 78.2 (22.8–156.6)
Black 12.9 (4.0–28.9) 1.8 (0.6–5.2) 39.0 (9.5–88.7)
Other 12.7 (8.3–39.9) 2.0 (1.9–7.4) 237.3 (187.1–302.4)
Co-morbidities
Diabetes Mellitus <0.0001 0.001 0.28
Yes 18.7 (8.1–34.9) 2.9 (1.2–6.4) 23.8 (4.2–86.2)
No 12.6 (6.6–24.3) 1.8 (0.9–4.3) 29.3 (6.9–108.7)
Cardiovascular disease 0.37 0.89 0.048
Yes 16.3 (7.1–30.3) 2.2 (1.0–5.2) 22.6 (3.7–82.6)
No 14.3 (7.1–27.3) 2.0 (1.0–5.0) 29.1 (6.9–117.0)
Malignancy 0.46 0.35 0.015
Yes 16.0 (7.5–25.9) 1.8 (1.1–3.6) 12.0 (2.9–83.0)
No 14.3 (7.0–27.8) 2.2 (1.0–5.1) 29.9 (6.5–106.6)
Renal diagnosis <0.0001 <0.0001 <0.0001
Ischaemic/hypertensive 13.6 (7.3–27.7) 2.1 (1.0–4.7) 12.4 (2.6–56.0)
Glomerulonephritis 8.2 (4.9–17.2) 1.4 (0.8–2.7) 70.5 (30.4–159.3)
Diabetic kidney disease 20.9 (10.4–51.8) 4.7 (1.6–8.1) 64.9 (23.0–237.3)
Polycystic kidney disease 12.0 (5.5–19.0) 1.5 (0.5–3.1) 10.2 (6.1–18.7)
Interstitial nephropathy 15.0 (8.1–27.3) 3.1 (1.1–5.0) 10.4 (3.6–35.0)
Reflux nephropathy 8.2 (3.7–22.8) 1.8 (0.6–3.9) 87.8 (29.3–141.0)
Other/uncertain 16.1 (7.4–31.0) 2.3 (1.0–5.7) 32.9 (6.9–113.5)
Estimated GFR -0.387 <0.0001 -0.340 <0.0001 0.100 0.027
CKD Stage <0.0001 <0.0001 0.22
G3a 8.6 (4.4–14.0) 1.3 (0.4–2.9) 23.0 (5.1–136.8)
G3b 12.6 (6.3–22.5) 1.8 (0.8–3.7) 27.9 (7.0–119.8)
G4 15.2 (7.5–27.8) 2.1 (1.0–5.1) 19.9 (4.4–78.0)
G5 29.5 (16.3–50.9) 5.3 (2.5–11.0) 33.2 (10.1–117.1)
Urinary ACR 0.400 <0.0001 0.516 <0.0001 N/A
Systolic blood pressure 0.184 <0.0001 0.179 <0.0001 0.227 <0.0001
Diastolic blood pressure 0.079 0.06 0.111 0.009 0.231 <0.0001
Serum κ FLC 0.513 <0.0001 0.479 <0.0001 0.175 <0.0001
Serum λ FLC 0.494 <0.0001 0.563 <0.0001 0.221 <0.0001
Urinary KCR N/A 0.925 <0.0001 0.400 <0.0001
Urinary LCR 0.925 <0.0001 N/A 0.516 <0.0001
Associations with continuous variables are expressed as Pearson’s r (after log transformation of both variables) and its corresponding P. For categorical variables,
median and interquartile ranges are shown with between-group differences assessed using the Mann-Whitney U or Kruskal-Wallis tests.
Abbreviations: ACR = albumin/creatinine ratio; CKD = chronic kidney disease; FLC = free light chains; GFR = glomerular filtration rate; IQR = interquartile range;
KCR = kappa/creatinine ratio; LCR = lambda/creatinine ratio.
https://doi.org/10.1371/journal.pone.0197043.t002
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Urinary FLC/Cr ratios were significantly higher in males, those of South Asian ethnicity,
and those with diabetic kidney disease, and significantly lower in those with glomerulonephri-
tis and polycystic kidney disease. However, these associations were no longer significant after
adjustment for ACR and eGFR. Patients with DM as a comorbidity had significantly higher
urinary FLC/Cr ratios, even after adjustment for eGFR, ACR, and serum FLC.
Scatter plots of the relationship between urinary FLC/Cr ratios with eGFR, ACR, and
serum FLC, are shown in Figs 1, 2 and 3, respectively. Urinary FLC/Cr ratios were most
strongly correlated with serum FLC; after adjustment for eGFR, ACR, DM, and renal diagno-
sis, a 10% higher serum kappa was associated with a 4.8% (3.4–6.2%) higher urinary KCR, and
a 10% higher serum lambda was associated with a 7.5% (5.8–9.3%) higher urinary LCR.
Progression to ESRD
During follow-up, 136 (24.5%) participants progressed to ESRD. A higher KCR and LCR were
both associated with a significantly increased risk of ESRD. The association between urinary
FLC/Cr ratios and risk of ESRD approximated a linear relationship, although there was a
smaller increase in risk per unit increase in urinary FLC/Cr ratio at the lower and upper
extremes of the range, as shown in Fig 4. A one SD higher KCR was associated with a HR of
1.58 (1.40–1.79) and a one SD higher LCR was associated with a HR of 1.47 (1.31–1.66). A uri-
nary FLC/Cr ratio above the 75th centile was associated with HRs of 3.18 (2.26–4.47) for KCR
and 3.67 (2.62–5.16) for LCR. The cumulative incidence of ESRD by quartiles of urinary FLC/
Cr are shown in Fig 5. The univariable associations between other baseline variables and risk
of ESRD are shown in Table 3.
Multivariable models incorporating urinary FLC/Cr ratios are shown in Table 4. Urinary
KCR and LCR both remained significantly associated with risk of ESRD after adjustment for
either eGFR (model 1) or ACR (model 2). However, after adjustment for both eGFR and ACR
(model 3), including models incorporating age, sex, ethnicity, renal diagnosis, MAP, eGFR,
and ACR (model 4), urinary KCR and LCR as continuous or spline predictor variables were
not significantly associated with risk of ESRD. The significant association between urinary
FLC/Cr ratios above the 75th centile and risk of ESRD did however remain in models 3 and 4.
When these analyses were repeated in participants with a urinary ACR< 30 mg/mmol
(N = 265), we found that higher urinary FLC/Cr ratios, as either continuous or categorical var-
iables, were associated with a significantly increased risk of ESRD on univariable analysis, but
the associations became non-significant after adjustment for eGFR.
Urinary FLC/Cr in risk stratification
After excluding those who died without ESRD within two years (N = 34) and those with less
than two years of follow-up (N = 58), 464 participants had data on ESRD at two years, of
whom 60 (12.9%) had reached ESRD. Measures of model performance for the prediction of
ESRD at two years are shown in Table 5, including the incremental value of adding urinary
FLC/Cr ratios to KFRE. The baseline model containing only KFRE had a strong predictive
ability for ESRD at two years (C-statistic 0.89 [95% CI 0.84–0.94]) and was well calibrated
(Hosmer-Lemeshow statistic 12.19, P = 0.14). None of the KFRE + KCR or KFRE + LCR mod-
els had a significant change in the C-statistic, suggesting no improvement in discrimination
between those who did and did not develop ESRD, nor any significant improvement in reclas-
sification of risk based on the IDI. Similarly, the addition of splines of KCR and LCR to the
KFRE model did not improve the C-statistic or show any improvement in discrimination
based on the IDI.
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Discussion
There is significant interest in identifying bioclinical prognostic factors in CKD that might
enhance our current models for risk stratification and potentially identify novel therapeutic
targets. This is to the best of our knowledge the first study to evaluate whether there is an
Fig 1. Scatter plots of urinary kappa/creatinine ratio (a) and lambda/creatinine ratio (b) by estimated glomerular
filtration rate. Scales are logarithmic. Abbreviations: GFR = glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0197043.g001
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independent association between urinary FLCs and risk of ESRD in patients with CKD. We
utilised a cohort of patients who were prospectively recruited with (i) a high risk of CKD pro-
gression; (ii) extended follow-up; (iii) a hard end-point; and (iv) a high proportion progressing
to the end-point.
Fig 2. Scatter plots of urinary kappa/creatinine ratio (a) and lambda/creatinine ratio (b) by urinary albumin/
creatinine ratio. Scales are logarithmic.
https://doi.org/10.1371/journal.pone.0197043.g002
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There was a negative correlation between eGFR and urinary FLC/Cr ratios, i.e. FLC/Cr
ratios increase as GFR falls, consistent with previously published data [13]. We hypothesise
that in patients with CKD, as nephrons are lost, there is hyperfiltration of the remaining func-
tional glomeruli and increased concentrations of FLC in the glomerular filtrate that exceeds
Fig 3. Scatter plots of urinary kappa/creatinine ratio by serum kappa (a) and urinary lambda/creatinine ratio by
serum lambda (b). Scales are logarithmic.
https://doi.org/10.1371/journal.pone.0197043.g003
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Fig 4. Restricted cubic splines of the subhazard ratio (solid line, with 95% confidence intervals shown as
interrupted lines) of end stage renal disease by urinary kappa/creatinine ratio (a) and urinary lambda/creatinine
ratio (b), adjusted for the competing risk of death. Percentiles are shown as vertical dotted lines. Abbreviations:
P = percentile.
https://doi.org/10.1371/journal.pone.0197043.g004
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the capacity of the proximal tubule to reabsorb and metabolise them. Tubular dysfunction
with decreased uptake of FLC may also contribute to increasing urinary FLC/Cr ratios.
There was also a positive correlation between urinary FLC/Cr ratios and ACR. Regardless
of the underlying cause of CKD, glomerular damage (associated with albuminuria and possibly
Fig 5. Cumulative incidence of end stage renal disease by quartiles of urinary kappa/creatinine ratio (a) and
lambda/creatinine ratio (b). Abbreviations: ESRD = end stage renal disease; KCR = kappa/creatinine ratio;
LCR = lambda/creatinine ratio; Q = quartile.
https://doi.org/10.1371/journal.pone.0197043.g005
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Table 3. Subhazard ratios with 95% confidence intervals in univariable competing-risk models for risk of end
stage renal disease accounting for the competing risk of death.
Variable Subhazard ratio (95% CI) P
Age 0.75 (0.65–0.87) <0.0001
Gender
Male 0.97 (0.68–1.36) 0.84
Female 1.04 (0.73–1.46) 0.84
Ethnicity
White 0.66 (0.47–0.93) 0.017
South Asian 1.50 (1.03–2.19) 0.036
Black 1.38 (0.82–2.31) 0.23
Comorbidities
Diabetes mellitus 0.90 (0.63–1.30) 0.58
Ischaemic heart disease 0.69 (0.44–1.08) 0.10
Cerebrovascular disease 1.18 (0.69–2.01) 0.55
Peripheral vascular disease 0.73 (0.37–1.43) 0.36
COPD 0.57 (0.29–1.13) 0.11
Malignancy 0.61 (0.34–1.09) 0.10
Renal diagnosis
Ischaemic/hypertensive 0.99 (0.67–1.45) 0.95
Glomerulonephritis 0.85 (0.51–1.41) 0.52
Diabetic kidney disease 1.64 (0.99–2.72) 0.06
Polycystic kidney disease 2.22 (1.34–3.69) 0.002
Interstitial nephropathy 0.71 (0.32–1.59) 0.40
Reflux nephropathy 0.30 (0.05–1.94) 0.21
Other/uncertain 0.90 (0.62–1.32) 0.60
Estimated GFR 0.25 (0.17–0.38) <0.0001
Urinary ACR 1.38 (1.20–1.58) <0.0001
Systolic blood pressure 1.28 (1.09–1.49) 0.002
Diastolic blood pressure 1.24 (1.04–1.48) 0.015
Serum κ FLC 1.67 (1.49–1.88) <0.0001
Serum λ FLC 1.57 (1.40–1.78) <0.0001
Serum κ+λ FLC 1.69 (1.50–1.91) <0.0001
Urinary KCR
Per +1 SD 1.58 (1.40–1.79) <0.0001
> 27.7 mg/mmol 3.18 (2.26–4.47) <0.0001
Urinary LCR
Per +1 SD 1.47 (1.31–1.66) <0.0001
> 5.1 mg/mmol 3.67 (2.62–5.16) <0.0001
Urinary KCR and LCR were analysed as both a continuous variable (per +1 SD) and a categorical variable (above
versus below the 75th centile). Subhazard ratios for continuous variables represent the risk associated with an increase
of one standard deviation.
Abbreviations: ACR = albumin/creatinine ratio; CI = confidence interval; COPD = chronic obstructive pulmonary
disease; FLC = free light chains; GFR = glomerular filtration rate; KCR = kappa/creatinine ratio; LCR = lambda/
creatinine ratio; SD = standard deviation; SHR = subhazard ratio
https://doi.org/10.1371/journal.pone.0197043.t003
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with increased filtration of FLCs) often coexists with tubulointerstitial fibrosis (and thus possi-
bly reduced tubular FLC reabsorption). The correlation between urinary albumin and FLC is
therefore not unexpected.
Adjustment for the confounding relationships with eGFR and ACR significantly attenuated
the association between FLC/Cr ratios as continuous predictor variables and risk of ESRD,
which became non-significant. The lack of an independent association may reflect their lack of
specificity for renal damage: urinary FLC/Cr ratios correlated most strongly with serum FLC,
suggesting that systemic inflammation may be an important determinant of urinary levels, and
urinary FLC concentration may also be influenced by mucosal secretion in the urinary tract,
although data do not exist on how much this pathway contributes.
Despite the lack of an independent association between FLC/Cr ratios and progression to
ESRD when analysed as full-range continuous variables, our multivariable analyses did show
Table 4. Subhazard ratios with 95% confidence intervals for urinary free light chain/creatinine ratios as continu-
ous and categorical (above 75th centile) predictors in multivariable competing risk models for end-stage renal dis-
ease, adjusted for the competing risk of death.
Model Subhazard Ratio (95% Confidence Interval)
Kappa/creatinine ratio Lambda/creatinine ratio
Per +1 SD > 27.7 mg/mmol Per +1 SD > 5.1 mg/mmol
1a 1.35 (1.19–1.55) 2.22 (1.55–3.18) 1.30 (1.14–1.49) 2.56 (1.78–3.68)
2b 1.43 (1.23–1.65) 2.55 (1.71–3.80) 1.32 (1.14–1.54) 2.79 (1.85–4.21)
3c 1.14 (0.96–1.36) 1.61 (1.05–2.49) 0.99 (0.78–1.24) 1.65 (1.05–2.60)
4d 1.22 (1.00–1.50) 1.74 (1.12–2.71) 1.00 (0.78–1.27) 2.05 (1.26–3.33)
Bold values have a P value < 0.05.
aAdjusted for eGFR.
bAdjusted for urinary ACR.
cAdjusted for eGFR and urinary ACR.
dAdjusted for age, sex, ethnicity, renal diagnosis, MAP, eGFR, and urinary ACR.
Abbreviations: ACR = albumin/creatinine ratio; eGFR = estimated glomerular filtration rate; FLC = free light chains;
MAP = mean arterial pressure; SD = standard deviation.
https://doi.org/10.1371/journal.pone.0197043.t004
Table 5. Logistic regression models for the prediction of end stage renal disease at two years, with measures of model performance and the incremental value of
adding kappa/creatinine ratio (KCR) or lambda/creatinine ratio (LCR) to a baseline model containing the kidney failure risk equation (KFRE).
Statistic Model
Kidney Failure Risk Equation (KFRE) KFRE + KCR KFRE + LCR
Per +1 SD > 27.6 mg/mmol Per +1 SD > 5.0 mg/mmol
Odds ratio (95% CI)
KFRE 1.10 (1.08–1.13) 1.10 (1.07–1.13) 1.10 (1.07–1.13) 1.10 (1.07–1.13) 1.09 (1.07–1.12)
KCR or LCR 1.05 (0.71–1.55) 1.54 (0.67–3.50) 1.16 (0.75–1.77) 2.67 (1.19–6.03)
R2 (Nagelkerke) 0.436 0.437 0.440 0.438 0.457
Hosmer-Lemeshow (P) 12.19 (0.14) 12.37 (0.14) 9.44 (0.31) 11.71 (0.16) 7.07 (0.53)
C-statistic (95% CI) 0.89 (0.84–0.94) 0.89 (0.84–0.94) 0.89 (0.84–0.94) 0.89 (0.83–0.94) 0.90 (0.85–0.95)
Δ C-statistic 0.00 (-0.01–0.01) 0.00 (-0.02–0.02) 0.00 (-0.01–0.01) 0.01 (-0.01–0.03)
IDI 0.00 (-0.01–0.02) 0.00 (-0.01–0.02) 0.00 (-0.01–0.02) 0.00 (-0.01–0.04)
Models were fitted with LCR and KCR as both continuous predictors (per +1 SD) and with a categorical cut-off above the 75th centile.
Abbreviations: CI = confidence interval; IDI = integrated discrimination improvement; KCR = kappa/creatinine ratio; KFRE = kidney failure risk equation;
LCR = lambda/creatinine ratio; SD = standard deviation.
https://doi.org/10.1371/journal.pone.0197043.t005
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that urinary FLC/Cr ratios above the 75th centile were independently associated with a signifi-
cantly increased risk of ESRD. It is possible that this is due to a nephrotoxic effect of FLCs, i.e.
those with the highest levels in the urine may be more likely to sustain FLC-induced tubular
damage, thus increasing their risk of CKD progression and ESRD. A nephrotoxic effect of
FLCs has been proposed as a possible explanation for an independent association between
serum FLC levels and progression to ESRD in patients with CKD, although the published data
on the relationship between serum FLC and progression to ESRD are inconsistent [28, 29].
Alternatively, the highest levels may be present in patients who have glomerular hyperfiltration
and/or tubular dysfunction, both factors that are associated with accelerated progression of
CKD. It is also possible that the association reflects a residual confounding effect of kidney
function that has not been fully accounted for by adjustment for creatinine-based eGFR.
Adding urinary FLC/Cr ratios to an established model for the estimation of two-year risk of
ESRD did not improve model performance in our cohort of patients with advanced kidney
disease. However, having previously been shown to be detectable prior to the development of
albuminuria, the use of urinary FLCs to stratify risk in early CKD could be examined in other
CKD cohorts with populations made up of less severe CKD.
The strength of this study is that it included a well-characterised cohort of patients with
prospective follow-up and a significant number of outcome events. Limitations were that it
was an observational study without mechanistic data, and we lacked a separate cohort to vali-
date our findings.
In conclusion, urinary FLCs have an association with progression to ESRD in patients with
CKD which appears to be explained largely by their correlation with eGFR and ACR, and the
current evidence suggests that measuring urinary FLC does not improve upon current models
for risk stratification.
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